Skip to content
value.today

Maverick Therapeutics Inc.

🇺🇸 Brisbane, California, USABiotechnologyFounded 2016
Total raised
$56 M
1 round on record
Latest round
$56 M
Jan 2017
First round on record
Jan 2017
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Maverick Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2017$56 MNo. 1$50 to $250 million

Maverick Therapeutics Inc.: Raise no. 1, Jan 2017

Investors in this round

5 investors had bought by the notice of Jan 19, 2017: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$56 M of $56 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Hans Peter Gerber · Executive Officer, Director
  • Bard Geesaman · Director
  • Christopher Arendt · Director
  • Dan Hicklin · Director
  • Lori Kunkel · Director
  • Luke Evnin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Hans Peter Gerber, Chief Science Officer and President. Newest notice filed Jan 19, 2017. Read the notice at the SEC.

equity, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Maverick Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2017).

    SEC Form D · Jan 2017

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jan 2017

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Maverick Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Maverick Therapeutics Inc.
NameRoleNamed in
Hans Peter GerberExecutive officerJan 2017
Bard GeesamanDirectorJan 2017
Christopher ArendtDirectorJan 2017
Dan HicklinDirectorJan 2017
Hans Peter GerberDirectorJan 2017
Lori KunkelDirectorJan 2017
Luke EvninDirectorJan 2017